In the USA, Medicaid is the principal payer of the health care costs of patients with HIV infection.
We wished to determine how the costs to Medicaid of patients in Maryland infected with HIV have changed in the setting of highly active antiretroviral treatment.
Observational cohort study.
Analysis of combined economic and clinical data of patients from the Johns Hopkins HIV Service, the provider of primary and sub-specialty care for a majority of HIV-infected patients in the Baltimore metropolitan region.
All patients were enrolled in Medicaid and received care longitudinally in Maryland from 1 January 1995 through 31 December 1997.
Monthly Medicaid payments were calculated for all inpatient and outpatient services by fiscal year, CD4 cell count, and use of protease inhibitors.
For inpatients with a CD4 cell count<50 x 106cells/l, the total health care average monthly payments remained unchanged ($2629 in 1995, $2585 in 1997).
Total mean monthly payments increased for those with a CD4 cell count>50 x 106 cells/l (CD4 cell count 50-200 x 106 cells/l, $1172 in 1995 and $1615 in 1997, P<0.05 ; CD4 cell count 201-500 x 106 cells/l, $1078 in 1995 and $1305 in 1997, P<0.05). (...)
Mots-clés Pascal : SIDA, Virose, Infection, Analyse coût efficacité, Chimiothérapie, Inhibiteur protease, Assurance maladie, Soin, Antiviral, Traitement, Homme, Dépense, Santé, Etude longitudinale, Coût, Immunopathologie, Immunodéficit, Economie santé, Medicaid, Protocole HAART
Mots-clés Pascal anglais : AIDS, Viral disease, Infection, Cost efficiency analysis, Chemotherapy, Protease inhibitor, Health insurance, Care, Antiviral, Treatment, Human, Expenditure, Health, Follow up study, Costs, Immunopathology, Immune deficiency, Health economy
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0305348
Code Inist : 002B02S05. Création : 16/11/1999.